Role of Early Left Atrial Functional Decline in Predicting Cardiotoxicity in HER2 Positive Breast Cancer Patients Treated With Trastuzumab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Role of Early Left Atrial Functional Decline in Predicting Cardiotoxicity in HER2 Positive Breast Cancer Patients Treated With Trastuzumab ; volume:24 ; number:6 ; day:2 ; month:5 ; year:2024 ; pages:550-562 ; date:6.2024
Cardiovascular toxicology ; 24, Heft 6 (2.5.2024), 550-562, 6.2024
- Creator
-
Bergamini, Corinna
Niro, Lorenzo
Springhetti, Paolo
Ferri, Luisa
Trento, Laura
Minnucci, Ilaria
Maffeis, Caterina
Tafciu, Elvin
Rossi, Andrea
Fiorio, Elena
Benfari, Giovanni
Ribichini, Flavio
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12012-024-09861-6
- URN
-
urn:nbn:de:101:1-2407291147161.821488451253
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bergamini, Corinna
- Niro, Lorenzo
- Springhetti, Paolo
- Ferri, Luisa
- Trento, Laura
- Minnucci, Ilaria
- Maffeis, Caterina
- Tafciu, Elvin
- Rossi, Andrea
- Fiorio, Elena
- Benfari, Giovanni
- Ribichini, Flavio
- SpringerLink (Online service)
Other Objects (12)
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer
Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
Late cardiotoxicity related to HER2-targeted cancer therapy
Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study
HER2+ breast cancer treatment and cardiotoxicity: monitoring and management
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer
Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
Late cardiotoxicity related to HER2-targeted cancer therapy
Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study
HER2+ breast cancer treatment and cardiotoxicity: monitoring and management
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer
Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
Late cardiotoxicity related to HER2-targeted cancer therapy
Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study
HER2+ breast cancer treatment and cardiotoxicity: monitoring and management